This is an old revision of this page, as edited by CrafterNova(talk | contribs) at 18:38, 13 October 2022(Adding local short description: "Nonsteroidal anti-inflammatory prodrug", overriding Wikidata description "chemical compound"). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 18:38, 13 October 2022 by CrafterNova(talk | contribs)(Adding local short description: "Nonsteroidal anti-inflammatory prodrug", overriding Wikidata description "chemical compound")
Indometacin farnesil (INN) is a prodrug of the nonsteroidal anti-inflammatory drug (NSAID) indometacin, designed to reduce the occurrence of side-effects by esterification of the carboxyl group on indometacin with farnesol. Indometacin farnesil was first approved in Japan in 1991, and is available in Japan and Indonesia, under the trade names Infree and Dialon, respectively.